As with all antacids, overdose may produce metabolic alkalosis. The product contains 27mmol of Sodium ions per 30ml and this should be considered. Management of overdose should include monitoring of plasma electrolytes and acid-base status, and general supportive measures.
Hypersensitivity to the active ingredient or to other ingredients of the product.
Not applicable
No further data is provided.
Non-particulate antacid for use by mouth to prior to general anaesthesia for caesarean section.
Citra pH has no relevant pharmacodynamic activity other than that caused by its alkalinity (e.g. its gastric acid neutralising capacity).
Citra pH is systemically absorbed and renally eliminated, causing metabolic alkalosis and urine alkalisation in sufficient doses.
Citra pH should not be administered to patients with metabolic or respiratory alkalosis, hypocalcaemia, or hypochlorhydria. Sodium containing salts should be administered extremely cautiously to patients with heart failure, oedema, renal impairment, hypertension, or aldosteronism. (During treatment of acidosis, frequent monitoring of serum-electrolyte concentrations and acid-base status is essential. Alkalinisation of the urine by bicarbonates or bicarbonate precursors leads to increased renal clearance of acidic drugs.) However, urinary alkalinisation prolongs the half-life of basic drugs and may result in toxicity.
Citrates and Citric Acid enhance intestinal aluminium absorption in renal patients which may lead to increased, harmful serum aluminium levels. It has therefore been suggested that patients with renal failure taking aluminium compounds to control phosphate absorption should not be prescribed citrate or citric acid containing products.
Not applicable
30ml of a 0.3M solution orally immediately prior to anaesthesia.
None
